Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204909 | 0.80 | CYP1A2 (0.48) | LMNACYP1A2CYP2D6GAADRD2 | |
| Hydrochloric Acid SCHEMBL5557868 | 0.79 | CYP1A2 (0.47) | LMNACYP1A2CYP2D6GAADRD2 | |
| SCHEMBL11531278 | 0.78 | MAPT (0.38) | LMNADRD2DRD4MAPTMEN1 | |
| SCHEMBL11532653 | 0.78 | DRD2 (0.40) | LMNACYP1A2CYP2D6DRD2DRD4 | |
| SCHEMBL11637517 | 0.76 | DRD2 (0.37) | LMNAGAADRD2DRD4MAPT | |
| SCHEMBL11531128 | 0.75 | NOX1 (0.35) | CHRM1PTGS2 | |
| SCHEMBL11531742 | 0.75 | GRM2 (0.38) | NOS2 | |
| SCHEMBL14156597 | 0.72 | LMNA (0.44) | LMNACYP1A2CYP2D6GAADRD2 | |
| SCHEMBL4836296 | 0.72 | LMNA (0.38) | LMNACYP1A2CYP2D6GAADRD2 | |
| SCHEMBL11635201 | 0.72 | DRD2 (0.54) | LMNACYP1A2CYP2D6GAADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063694-A1 | Compound useful for the treatment of CNS disorders | BROWDER MONTE R (US) | 2004-04-01 | — | — | US | disclosed |
| WO-2003104239-A1 | COMPOUND FOR THE TREATMENT OF CNS DISORDERS | IVAX CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-4172831-A | CENTRAL NERVOUS SYSTEM | LILLY INDUSTRIES LIMITED (GB) | 1979-10-30 | — | — | US | disclosed |
| US-4115574-A | CNS ACTIVITY | LILLY INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
| US-4115568-A | CNS ACTIVITY | LILLY INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063694-A1 | Compound useful for the treatment of CNS disorders | HMGCR, GRIN2C, CYP11B2 | LMNA 2840/4885CYP1A2 101/4885CYP2D6 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.